Integrating Computational Methods and Drug Discovery – Avoiding pitfalls in chemical space By Alexandre Ismail and Professor Philippe Manivet The immensity of the task in discovering suitable molecules for development among the vast number which are theoretically available is well stated. With 90% of potentially efficacious compounds… Read More
Predictive tests and personalised medicine By Dr Eddie Blair Acceptance of the personalised medicines paradigm is strictly dependent on this approach clearly benefiting patients with minimal effects on the actual delivery of healthcare. The use of molecular diagnostics to predict how an individual will respond to… Read More
Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry… Read More
By Dr John Comley After nearly 15 years of challenging maturity 1536 plate adoption (particularly in primary screening), finally appears to have taken hold. There is now available a broad range of 1536 plate types; an ever expanding variety of tools that make… Read More
Himarnessing fragment-based drug discovery at CRT By Dr Andrew P Turnbull and Dr Martin E Swarbrick In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary… Read More
Structure-Based Drug Design – Will crystallisation ‘chaperones’ make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have… Read More
By Dr Susanta K. Sarkar The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment… Read More
Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack… Read More
Share Share Tweet Email Stem Cell Therapies: Assessing the commercial opportunity Stem Cell Therapies: Assessing the commercial opportunity By Su Webber, Andrew Millest and Mark Williams Restructuring and reorganisation is routine and relentless in… Read More
Bringing Cost and Process Efficiency to Next Generation Sequencing By Dr Fred P. Ernani, and Dr Emily M. LeProust While next-generation sequencing has revolutionised the way genomes are sequenced, this technology possesses a fundamental weakness – the inability to easily target specific regions of a genome. To… Read More
Automation Of Solid/Powder Dispensing: Much needed, but cautiously used! By Dr John Comley This article investigates solid/powder dispensing in pharma and biotech, examines where it is most used, whether there exists a need to apply automation and what is motivating its wider use today. It reveals how concerns… Read More
Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety,… Read More
Modular Automation for Screening: A cost/benefit analysis By Dr Jonathan Wingfield Cost is now a key driver for pharmaceutical companies and in many respects shapes the capital, revenue and resource decisions that have to be made during the drug discovery process. Where companies are resource rich, the need… Read More
LIMS vs ELNs – Arch enemies or best of friends? By David Morris Since the first appearance of laboratory information management systems (LIMS) in the late 1960s, this technology has become commonplace in many, if not most, research and commercial laboratories. This considerable development… Read More
Recent Technology Advances Transforming Pharmaceutical Drug Discovery and Development By Dr Coiln Brenan, and Dr Bill LaMarr The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more… Read More
Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may… Read More
